New Scientific Board Member

Prof. PhD David Ander­son
Bur­net Insti­tute, Mel­bourne, Aus­tralia, Deputy Direc­tor, Bur­net Senior Prin­ci­pal Fel­low.

Pro­fes­sor Ander­son is an expert in Micro­bi­ol­o­gy and Mol­e­c­u­lar Virol­o­gy. He has focused his work on under­stand­ing the struc­ture and assem­bly of hepati­tis virus­es, and the use of this infor­ma­tion to design bet­ter diag­nos­tics, vac­cines and antivi­ral ther­a­pies for con­trol of major viral infec­tions of man. Pro­fes­sor Ander­son has pub­lished more than 60 orig­i­nal research papers and invit­ed chap­ters, and has been invit­ed to speak on orig­i­nal research work at numer­ous nation­al and inter­na­tion­al sci­en­tif­ic meet­ings. He has been active in trans­la­tion of research into prac­ti­cal out­comes through com­mer­cial ven­tures and aca­d­e­m­ic col­lab­o­ra­tions and is an inven­tor on 10 patent fam­i­lies.

We are real­ly proud to wel­come Pro­fes­sor Ander­son as our new board mem­ber and we are pleased that he will sup­port ARTES. We are look­ing for­ward to a suc­cess­ful rela­tion­ship.

BIO 2011, Washington DC

Meet us at the part­ner­ing “Busi­ness Forum” event of the Bio Inter­na­tion­al Con­ven­tion 2011 in Wash­ing­ton DC or con­tact us direct­ly for a per­son­al meet­ing!

The Bio 2011 is tak­ing place from June 27 — 30.
Go to BIO web­site

ARTES steps further into the vaccine business by acquiring Anavax

ARTES Biotech­nol­o­gy announces today the acquire­ment of the ANAVAX virus-like par­ti­cle (VLP) tech­nol­o­gy from Select Vac­cines Ltd. ANAVAX is a patent-pro­tect­ed VLP tech­nol­o­gy that can be applied to the pre­ven­tion of sev­er­al infec­tious dis­eases.

With the com­bi­na­tion of two excel­lent tech­nol­o­gy plat­forms, ANAVAX and the Hansenu­la expres­sion sys­tem, ARTES has posi­tioned itself as a unique part­ner for the vac­cine indus­try.

The ANAVAX VLP plat­form has already been applied to the devel­op­ment of adju­vant-free vac­cines against avian and swine flu, malar­ia and HIV. Hansenu­la is the pre­ferred tech­nol­o­gy for afford­able mass vac­ci­na­tion and is rec­om­mend­ed by the WHO for hepati­tis B vac­ci­na­tion cam­paigns. Togeth­er, the plat­forms build a new approach to low-cost mass pro­duc­tion of safe and effec­tive vac­cines. ARTES’ busi­ness plan is to enhance its posi­tion as a pre­ferred devel­op­ment part­ner for vac­cine man­u­fac­tur­er.

Injectable Sustained Release Formulations of Therapeutic Proteins

Q Chip Ltd and ARTES Biotech­nol­o­gy GmbH announce that they have signed a Col­lab­o­ra­tive Agree­ment to explore the co-devel­op­ment of a new sus­tained release for­mu­la­tion of inter­fer­on alpha 2a for the treat­ment of chron­ic hepati­tis B and C.

The study is designed to eval­u­ate Q Chip’s Q‑Sphera™ pep­tide and pro­tein deliv­ery plat­form to devel­op a new sus­tained release micros­phere for­mu­la­tion com­posed of bio­com­pat­i­ble poly­mers loaded with inter­fer­on alpha 2a man­u­fac­tured from ARTES´ pro­pri­etary yeast Hansenu­la poly­mor­pha expres­sion sys­tem.

Q‑Sphera™ is a high­ly enabling bio-encap­su­la­tion tech­nol­o­gy for the devel­op­ment of poly­mer based sus­tained release sys­tems. No harsh sol­vents or man­u­fac­tur­ing con­di­tions are used in the pro­duc­tion of drug (includ­ing pep­tides and pro­teins) loaded micros­pheres facil­i­tat­ing benign pro­cess­ing of labile mol­e­cules.
Hansenu­la based prod­ucts, which are already mar­ket­ed world­wide, are char­ac­ter­ized by safe­ty and cost effi­cien­cy supe­ri­or to oth­er micro­bial tech­nolo­gies. Inter­fer­on alpha 2a man­u­fac­tured from Hansenu­la has proven to be bet­ter tol­er­at­ed than the E. coli ref­er­ence.

The col­lab­o­ra­tion aims to improve patient com­pli­ance and pro­vide a more con­ve­nient dos­ing sched­ule com­pared with cur­rent mar­ket­ed pegy­lat­ed ther­a­pies through the devel­op­ment of a one month sus­tained release micros­phere for­mu­la­tion. This first phase of the col­lab­o­ra­tion is expect­ed to be com­plet­ed by the end of 2010.

http://www.q‑chip.com

ARTES and Rhein Minapharm continue their successful product development collaboration

Lan­gen­feld and Cairo – ARTES Biotech­nol­o­gy and Rhein Minapharm Bio­genet­ics joint­ly announced the suc­cess­ful pro­duc­tion of a new tar­get of a ther­a­peu­tic pro­tein. This is the first result of a long-term research col­lab­o­ra­tion that was signed in Jan­u­ary 2008. Con­se­quent­ly, the two com­pa­nies extend­ed their col­lab­o­ra­tion in May 2009.

ARTES applied its pro­pri­etary Hansenu­la tech­nol­o­gy plat­form and know-how to the gen­er­a­tion of a ther­a­peu­tic pro­tein cho­sen by Rhein Minapharm that is typ­i­cal­ly pro­duced in E coli. Rhein Minapharms´s new tar­get is now pro­duced from the Hansenu­la plat­form at con­sid­er­able high­er yields and at reduced costs com­pared to alter­na­tive bac­te­r­i­al or yeast sys­tems.

Under the terms of agree­ment ARTES hand­ed over the pro­duc­tion cell lines and received anoth­er mile­stone pay­ment. Addi­tion­al­ly, ARTES and Rhein Minapharm extend­ed their col­lab­o­ra­tion aim­ing at addi­tion­al tar­gets for Minapharm´s port­fo­lio. ARTES will be respon­si­ble for the gen­er­a­tion of new pro­duc­tion cell lines and will share the process research and devel­op­ment respon­si­bil­i­ty with Minapharm.

Our long-term agree­ment is an impor­tant mile­stone in the exist­ing rela­tion­ship between our com­pa­nies and we are real­ly proud that our strain and process devel­op­ment work enables Rhein Minapharm to devel­op their inno­v­a­tive tar­get pipeline and to save pro­duc­tion costs,” said Dr. Michael Pio­ntek, founder and Man­ag­ing Direc­tor of ARTES.

Dr. Wafik Bardis­si, Chair­man and CEO of Minapharm added:
“Togeth­er with ARTES, we are cre­at­ing a cross-func­tion­al R&D team­work to fur­ther endow our pipeline with afford­abil­i­ty and inno­va­tion, char­ac­ter­is­tic of Hansenu­la derived pro­teins already in clin­i­cal prac­tice and key mar­ket dri­vers of our emerg­ing mar­kets.”

http://www.minapharm.com

ARTES is research partner of ChemBioTec project supported by Deutsche Stiftung Umwelt

ARTES Biotech­nol­o­gy today announces the col­lab­o­ra­tion with 5 oth­er col­lab­o­ra­tion part­ners in a joint 28 months research pro­gram that is grant­ed by the nation­al Deutsche Stiftung Umwelt with­in the Chem­BioTec ini­tia­tive. The Deutsche Bun­dess­tiftung Umwelt DBU is one of Europe’s largest foun­da­tions and pro­motes inno­v­a­tive and exem­plary envi­ron­men­tal projects

The fund­ed project includes three aca­d­e­m­ic part­ners and three biotech com­pa­nies and is coor­di­nat­ed by Prof. Dr. Hol­ger Zorn, Insti­tute of food chem­istry and food biotech­nol­o­gy, Uni­ver­si­ty Giessen.
The inter­dis­ci­pli­nary research group has set the aim to study in a first time appli­ca­tion the mate­r­i­al recy­cling of straw and wood left­overs by using a fun­gus secre­tome.
With this project ARTES extends its activ­i­ties in the area of pro­duc­tion of bio-based fine chem­i­cals from renew­able resources.

Exclusive Cooperation between ARTES and the Ukrainian National Academy of Sciences

Langenfeld/Lviv, August 5th, 2009

ARTES announced today that it has signed an exclu­sive Mar­ket­ing Agree­ment with the Insti­tute of Cell Biol­o­gy of the Nation­al Acad­e­my of Sci­ence of Ukraine. Mat­ter of the agree­ment is that the NAS tech­nol­o­gy based on the yeast organ­ism Hansenu­la poly­mor­pha is now exclu­sive­ly mar­ket­ed and licensed by ARTES Biotech­nol­o­gy world­wide except for Ukraine.

The tech­nol­o­gy licensed to ARTES cov­ers new expres­sion tools as well as pro­duc­tion cell lines for var­i­ous prod­ucts, a.o. HepB anti­gen and Arginase. With this agree­ment ARTES expands its Hansenu­la tech­nol­o­gy plat­form and gains access to new process­es and prod­ucts.

With the input from NAS”, said Michael Pio­ntek the man­ag­ing direc­tor from ARTES, “we are now once again able to broad­en up our exper­tise in the Hansenu­la research field. This newest col­lab­o­ra­tion enables us even more to expand our pre­vi­ous offer and espe­cial­ly with the view of East-Euro­pean mar­kets we had won an impor­tant aca­d­e­m­ic research part­ner.”

ARTES enters into a partnership with Henkel in a 3‑year research program

ARTES Biotech­nol­o­gy GmbH today announces the col­lab­o­ra­tion with Henkel in a joint three years research pro­gram that is grant­ed by the Ger­man nation­al BMBF (Ger­man Min­is­tery of Edu­ca­tion and Research) with­in the CLIB2021 clus­ter (Wet­tbe­werb Indus­trielle Biotech­nolo­gie 2021). The coop­er­a­tion aims at the devel­op­ment and man­u­fac­tur­ing of pep­tides with adhe­sive prop­er­ties.

ARTES will apply its pro­pri­etary tech­nol­o­gy plat­forms – the yeast expres­sion tech­nolo­gies Hansenu­la and Arx­u­la and the Chap­er­one tech­nol­o­gy for improved secre­tion. The gen­er­a­tion of pro­duc­tion cell lines, ana­lyt­i­cal assay devel­op­ment, and lab-scale fermentation/down stream process devel­op­ment are ARTES´ respon­si­bil­i­ties in this coop­er­a­tion. Inno­v­a­tive strate­gies for the pro­duc­tion of dif­fi­cult-to-express adhe­sive pep­tides shall be devel­oped, result­ing in next gen­er­a­tion tools for ARTES´ con­tract R&D.

New Scientific Board Member

Prof. Dr. em. Her­mann Sahm

As the for­mer direc­tor of the Insti­tute of Biotech­nol­o­gy at the Research Cen­ter of Jülich, Prof. Dr. em. Her­mann Sahm‘s main fields of inter­est in the last three decades were phys­i­ol­o­gy, enzy­mol­o­gy and mol­e­c­u­lar biol­o­gy of biotech­ni­cal amino acid, vit­a­min and ethanol pro­duc­tion by means of a vari­aty of dif­fer­ent microor­gan­isms. He is an expert in the field of improve­ment and opti­miza­tion of pro­duc­tion strains by meta­bol­ic engi­neer­ing. We are real­ly proud to wel­come Prof. Dr. em. Sahm as our new board mem­ber and we would be pleased that he will sup­port ARTES Biotech­nol­o­gy as con­sul­tant and net­work part­ner. We are look­ing for­ward to a suc­cess­ful rela­tion­s­ship.

New Scientific Board Member

Prof. Dr. Hol­ger Zorn,
Uni­ver­si­ty of tech­nol­o­gy, Dort­mund, leader of the work group tech­no­log­i­cal bio­chem­istry.

Prof. Dr. Zorn is an expert in the field of indus­tri­al bio­engi­neer­ing and white biotech­nol­o­gy and here in detail for extrac­tion of enzymes from basid­iomycete fun­gi. We are real­ly proud to wel­come Prof. Zorn as our new board mem­ber and we would be pleased that he will sup­port ARTES Biotech­nol­o­gy as con­sul­tant and net­work part­ner. We are look­ing for­ward to a suc­cess­ful rela­tion­ship.